Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826

Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer in the phase 3, randomized, double‐blind, placebo‐controlled KEYNOTE‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Shin, Yonemori, Kan, Usami, Tomoka, Minobe, Shinichiro, Yunokawa, Mayu, Iwata, Takashi, Okamoto, Aikou, Aoki, Yoichi, Itamochi, Hiroaki, Takekuma, Munetaka, Harano, Kenichi, Yamamoto, Keiko, Maruko, Takeshi, Ugai, Hiroyuki, Tekin, Cumhur, Colombo, Nicoletta, Fujiwara, Keiichi, Hasegawa, Kosei, Ushijima, Kimio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633308/
https://www.ncbi.nlm.nih.gov/pubmed/35792064
http://dx.doi.org/10.1111/cas.15479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633308/
https://www.ncbi.nlm.nih.gov/pubmed/35792064
http://dx.doi.org/10.1111/cas.15479

Ejemplares similares